Introduction {#s1}
============

Cutaneous adverse drug reactions (cADRs) are common adverse reactions observed in patients using antiepileptic drugs (AEDs). Studies have demonstrated that the incidence of AEDs-cADRs was about 3.61%. Also, cADRs are relatively common with the use of aromatic antiepileptic drugs (AAEDs), including carbamazepine (CBZ), phenytoin (PHT), lamotrigine (LTG), and phenobarbital (PB) ([@B1]). They manifest as ordinary maculopapular eruption (MPE), eventually leading to serious life-threatening conditions such as hypersensitivity syndrome (HSS), Steven-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN). AEDs-cADRs often lead to drug discontinuation in patients with epilepsy, resulting in the inability to control seizures. A 40% mortality rate has been reported in patients with severe cADRs ([@B2]).

Since 2004, a number of studies have suggested a strong association of HLA genotype with the occurrence of AEDs-cADRs. However, this association differs between different races and areas ([@B3]--[@B5]). In China, the majority of studies have been carried out in southern Chinese Han population ([@B6]--[@B8]). Since the seventh century, central Asians, Arabs, and Persians have migrated to China and settled to gradually form the Hui ethnicity. Some studies have suggested genetic differences between the Hui and the Han ([@B9]). Ningxia, located in Northwest China, has the largest Hui population in China. Therefore, Ningxia is an ideal state to study regional and ethnic differences. A nested case-control study was conducted in patients who were AEDs-cADRs and AEDs tolerant to determine the association between HLA genotypes and patients with AEDs-cADRs in Ningxia.

Materials and Methods {#s2}
=====================

Study Participants
------------------

Study participants were patients diagnosed with epilepsy by the Department of Neurology in Ningxia Medical University General Hospital. The inclusion criteria were as follows: ① Ningxia resident with no history of marriages with other ethnic groups for more than three generations; ② Clear indications for AEDs treatment; ③ Have not been administered oral AEDs, and potential adverse drug reactions declared in patients or their guardians, after which signed informed consents were obtained; and ④ The initial dose and increasing dose of AEDs determined according to the "Pharmacopeia of People\'s Republic of China" (2010 edition). The exclusion criteria were as follows: ① Having a history of alcohol-related epilepsy; ② Having a treatable cause (such as metabolic disorders, poisoning, and infection); ③ With progressive brain or central nervous system diseases, such as encephalitis, tumors, or degenerative diseases; ④ Suffering from other diseases and the emergence of allergy during the follow-up period; and ⑤ Having to discontinue or substitute medications and not completing 12 weeks of prescribed oral AEDs.

Four hundred and fifteen patients were followed up bi-weekly for 12 weeks after initiating oral AEDs. The initial dosage of PHT, LTG, CBZ, and valproate (VPA) was 200, 500, 12.5, 100 mg/d, and 5 mg/kg/d, respectively. They were examined for symptoms and signs of cADRs in an epileptic clinic every 2 weeks. AEDs tolerance was defined as patients who were able to tolerate AEDs without cADRs manifestation. If cADRs manifested, the AEDs were discontinued immediately and a dermatologist was consulted to diagnose and treat the patients ([Figure 1](#F1){ref-type="fig"}).

![Flow chart of the nested case-control study.](fneur-10-00001-g0001){#F1}

Two attending or one chief physician from the Department of Dermatology examined the patients. The criteria for the diagnosis and classification of cADRs were as follows: ① MPE: a rash, not involving the mucosa, no organ or system damage, and resolved after 1--2 weeks; ② HSS: in addition to skin rash, numerous viscera involvement with systemic manifestations, such as fever, arthralgia, eosinophilia, and lymphadenopathy; ③ SJS: the occurrence of skin exfoliation, involving a range of no \<10% of the body area, with or without other organ or system damage; ④ TEN: the presence of skin exfoliation, involving more than 30% of the body area, with or without other organ or system damage; and ⑤ SJS/TEN: the presence of skin exfoliation, involving a range of 10--30% of the total body area. The patients were treated for skin damage based on the severity as determined by a dermatologist after cADRs diagnosis was confirmed. These patients were assigned to the AEDs-cADRs group.

Nested case-control design is the most common way to reduce the costs of exposure assessment in prospective epidemiological studies. They can also reduce the sample size through matching ([@B10]). In this study, 15 patients with epilepsy who developed cADRs were defined as the AEDs-cADRs group. For each patient with AEDs-cADRs, two patients with AEDs tolerance were selected and matched by AEDs, gender, age (±3 years), and ethnicity.

Clinical Data Collection
------------------------

A unified AEDs-cADRs epidemiological questionnaire, including demographics, underlying diseases, medication history, allergies, and seizure history, was used. The occurrence of cADRs during the 12 weeks was recorded, including the date of cADRs manifestation and other clinical manifestations involving the mucosa and subtypes.

Ethics Statement
----------------

The General Hospital of Ningxia Medical University Ethics Committee approved the study. Also, the study was performed in compliance with the Helsinki Declaration. Access to the patient information database was granted by the General Hospital of Ningxia Medical University and approved by the ethics committee following study review. All enrolled patients agreed to have their data published and signed a written informed consent form.

HLA-A, HLA-B, and HLA-DRB1 Genotyping
-------------------------------------

Peripheral venous blood (3 mL) from each participant was collected in anticoagulant tubes. An extraction kit (Beijing Tiangen Biotech Company, China) was used to extract genomic DNA from whole blood according to the manufacturer\'s protocols. HLA genotype was performed using PCR-SBT at the Beijing Boao Crystal Biotechnology Company, China. The following procedural steps were adopted: ① amplification of HLA-A, HLA-B, and HLA-DRB1 loci; ② purification and detection of the amplified products; and ③ HLA genotyping sequencing using a 3730XL ABI detector.

Statistical Analysis
--------------------

Continuous variables were expressed as mean and standard deviation (SD) and categorical variables as frequencies (%). The Pearson chi-squared test was used to compare categorical variables and the Student *t*-test to compare continuous variables. Differences in HLA genotype frequency between the groups were analyzed using the Fisher\'s exact test. Risk association between HLA alleles and AEDs-cADRs were presented as odds ratios (OR) and 95% confidence intervals (CI). *P*-values and 95% CIs were estimated using two-tailed tests. Data were analyzed using SPSS13.0 software.

Results {#s3}
=======

Characteristics of the Study Participants
-----------------------------------------

The age of the 15 patients with AEDs-cARDs ranged from 14 to 60 years old, with an average age of 39.2 ± 15.4 years old. These included 10 male patients and 5 female patients with a ratio of 2:1. Twelve patients were of Han ethnicity and three of Hui ethnicity. Ten patients were with generalized epileptic seizures and five were with partial epileptic seizures. One patient had a pollen allergy history. One patient received PHT that induced cADRs, two patients received CBZ, two received LEV, one received VPA, and nine received LTG. Moreover, there were 14 patients with MPE and one Hui female patient with HSS who accepted treatment after onset. Further, five patients had cADRs after taking the initial dose of AEDs, of which one patient received CBZ, one received LEV, and three received LTG. The average time from patients taking AEDs to the occurrence of cADRs was 93.4 ± 70 days, with the longest latency period being 6 months and the shortest being 1 day ([Table 1](#T1){ref-type="table"}).

###### 

The characteristics of AEDs-cADRs group.

  **AEDs-cADRs group**   **Gender**   **Age (years)**   **Ethnicity**   **Address (city)**   **Allergy history**   **Type of AEDs**   **Daily dose**   **Time of occurrence**   **Type of cARDs**
  ---------------------- ------------ ----------------- --------------- -------------------- --------------------- ------------------ ---------------- ------------------------ -------------------
  C01                    M            19                Han             Zhongning            No                    PHT                300 mg           After 6 m                MPE
  C02                    M            14                Han             Shizuishan           No                    LEV                1250 mg          After 5 d                MPE
  C03                    F            20                Han             Yinchuan             No                    CBZ                100 mg           After 6 d                MPE
  C04                    M            41                Han             Yinchuan             No                    CBZ                200 mg           After 43 d               MPE
  C05                    F            25                Han             ShiZuiShan           No                    LTG                6.25 mg          After 5 d                MPE
  C06                    F            31                Hui             Yinchuan             YES                   LTG                50 mg            After 7 d                MPE
  C07                    M            14                Han             ShiZuiShan           No                    LEV                500 mg           After 1 m                MPE
  C08                    M            27                Han             ShiZuiShan           No                    LTG                12.5 mg          After 2 m                MPE
  C09                    F            41                Hui             Pengyang             No                    LTG                25 mg            After 1 m                HSS
  C10                    M            55                Han             Yinchuan             No                    LTG                25 mg            After 2 m                MPE
  C11                    M            40                Hui             Yongning             No                    LTG                50 mg            After 15 d               MPE
  C12                    M            22                Han             Jingyuan             No                    LTG                25 mg            After 13 d               MPE
  C13                    M            60                Han             ZhongNing            No                    VPA                400 mg           After 1 d                MPE
  C14                    F            16                Han             Guyuan               No                    LTG                12.5 mg          After 10 d               MPE
  C15                    M            55                Han             Yinchuan             No                    LTG                25 mg            After 5 d                MPE

The age of the 30 AEDs tolerant patients ranged from 12 to 65 years old, with an average age of 31.7 ± 12.4 years old. These included 19 male patients and 11 female patients at a ratio of 1.7:1. Further, 26 patients were of Han ethnicity and 4 were of Hui ethnicity. Twenty-three had generalized seizures, and seven had partial seizures. Moreover, two received PHT, four received LEV, four received CBZ, two received VPA, and eighteen received LTG ([Table 2](#T2){ref-type="table"}).

###### 

The characteristics of AEDs tolerant group.

  **AEDs tolerant group**   **Gender**   **Age (years)**   **Ethnicity**   **Address (city)**   **Type of AEDs**   **AEDs tolerance group**   **Address (city)**   **Gender**   **Age (years)**   **Ethnicity**   **Type of AEDs**
  ------------------------- ------------ ----------------- --------------- -------------------- ------------------ -------------------------- -------------------- ------------ ----------------- --------------- ------------------
  M01                       M            24                Han             Qingtongxia          PHT                M16                        Yongning             M            26                Han             LTG
  M02                       M            24                Han             Yongning             PHT                M17                        Yongning             F            25                Hui             LTG
  M03                       M            17                Han             Jingyuan             LEV                M18                        Yongning             F            25                Hui             LTG
  M04                       M            24                Han             Yanchi               LEV                M19                        Yinchuan             M            30                Han             LTG
  M05                       F            27                Han             Helan                CBZ                M20                        Yinchuan             M            65                Han             LTG
  M06                       F            25                Han             Zhongwei             CBZ                M21                        Helan                M            35                Han             LTG
  M07                       M            45                Han             Wuzhong              CBZ                M22                        Helan                M            36                Han             LTG
  M08                       M            39                Han             Zhongning            CBZ                M23                        Shizuishan           M            17                Han             LTG
  M09                       F            17                Han             Yingchuan            LTG                M24                        Zhongwei             M            28                Han             LTG
  M10                       F            22                Han             Yongning             LTG                M25                        Zhongwei             M            32                Han             VPA
  M11                       F            27                Hui             Yongning             LTG                M26                        Yinchuan             M            12                Han             VPA
  M12                       F            20                Hui             Yanchi               LTG                M27                        Qingtongxia          F            20                Han             LTG
  M13                       F            23                Han             Yinchuan             LEV                M28                        Helan                F            44                Han             LTG
  M14                       M            21                Han             Yinchuan             LEV                M29                        Helan                M            23                Han             LTG
  M15                       M            35                Han             Helan                LTG                M30                        Zhongning            M            30                Han             LTG

Genotypes of HLA-A, HLA-B, and HLA-DRB1
---------------------------------------

In the AEDs-cADRs group, the number of HLA-A, HLA-B, and HLA-DRB1 genotypes detected was 12, 18, and 15, respectively. Higher distribution frequencies of HLA-A genotype were A^\*^0207 (16.67%) and A^\*^2402 (13.33%). The highest distribution frequency of HLA-B genotype was B^\*^5101 (20%). The distribution frequency of A^\*^0201, A^\*^0206, A^\*^3101, A^\*^3303, B^\*^3501, DRB1^\*^0701, DRB1^\*^0803, DRB1^\*^0901, DRB1^\*^1101, DRB1^\*^1202, and DRB1^\*^1454 was 10% ([Table 3](#T3){ref-type="table"}).

###### 

Genotypes of HLA-A, HLA-B, and HLA-DRB1 in AEDs-cADRs group.

  **AEDs-cADRs group**   **Type of AEDs**   **Type of cADRs**   **HLA sub-type**                               
  ---------------------- ------------------ ------------------- ------------------ ------ ------ ------ ------ ------
  C01                    PHT                MPE                 3201               3303   3501   4403   0405   0803
  C02                    LEV                MPE                 0207               3201   4601   5201   0901   1202
  C03                    CBZ                MPE                 1101               2402   1505   5101   0803   1210
  C04                    CBZ                MPE                 0201               2402   1518   5101   1101   1454
  C05                    LTG                MPE                 0201               0207   1501   4801   0405   1405
  C06                    LTG                MPE                 0203               0207   4601   5801   0301   1454
  C07                    LEV                MPE                 0206               1101   1518   3501   0401   1501
  C08                    LTG                MPE                 0206               3303   4403   5101   1302   1454
  C09                    LTG                HSS                 2402               3101   2705   5101   0101   0701
  C10                    LTG                MPE                 0201               2402   1302   1501   0701   1501
  C11                    LTG                MPE                 0101               0206   1301   5701   0401   0901
  C12                    LTG                MPE                 2901               3101   0705   5101   0803   1202
  C13                    VPA                MPE                 3101               3303   4006   5102   1101   1101
  C14                    LTG                MPE                 0207               1101   3501   4002   0901   1202
  C15                    LTG                MPE                 0207               3001   1302   5101   0701   1201

*In the HLA naming protocol,"^\*^" separates the HLA locus (A, B and DRB1) from the serotype (32, 33 and 35), eg. HLA-A^\*^ 3201*.

In the AEDs tolerant group, the number of HLA-A, HLA-B, and HLA-DRB1 genotypes detected was 13, 26, and 23, respectively. Higher distribution frequencies of the HLA-A genotype were A^\*^0201 (21.67%) and A^\*^1101 (20%). The distribution frequency of the HLA-B genotype was lower than 10%. Higher distribution frequency of the HLA-DRB1 genotype was DRB1^\*^0901 (15%), followed by DRB1^\*^0301(10%) and DRB1^\*^1202 (10%) ([Table 4](#T4){ref-type="table"}).

###### 

Genotypes of HLA-A, HLA-B, and HLA-DRB1 in AEDs tolerant group.

  **AEDs tolerant group**   **Type of AEDs**   **HLA sub-type**                               
  ------------------------- ------------------ ------------------ ------ ------ ------ ------ ------
  M01                       PHT                1101               2601   0801   4001   0301   0405
  M02                       PHT                1101               1101   3503   5102   1101   1123
  M03                       LEV                1101               2402   0702   5401   0405   1501
  M04                       LEV                1101               1101   0702   4001   0101   0901
  M05                       CBZ                0201               0201   4003   6701   1302   1405
  M06                       CBZ                1101               3303   5201   5801   0301   0803
  M07                       CBZ                0302               1101   0801   1502   0301   1202
  M08                       CBZ                0201               3303   1501   5001   0701   1101
  M09                       LTG                0207               1101   0702   5101   0901   1501
  M10                       LTG                0201               3004   5801   5801   0410   1454
  M11                       LTG                1101               3001   1302   5201   0701   1502
  M12                       LTG                0201               3303   1301   5801   0301   1202
  M13                       LEV                0201               0301   3502   4101   0101   0301
  M14                       LEV                0101               3001   1302   3503   1103   1301
  M15                       LTG                0101               0201   4002   4601   1101   1202
  M16                       LTG                0101               0101   4001   4001   1454   1454
  M17                       LTG                2402               2402   3802   5101   1201   1312
  M18                       LTG                2402               3001   3503   5401   1101   1501
  M19                       LTG                0203               3303   1801   5502   1104   1602
  M20                       LTG                0301               3303   5201   5801   0301   1502
  M21                       LTG                0201               2402   1501   5101   0901   1001
  M22                       LTG                1101               3101   0702   4001   0101   0901
  M23                       LTG                0201               2601   4006   4006   0803   0901
  M24                       LTG                3001               3101   1302   5101   0701   1454
  M25                       VPA                0201               0201   4006   4601   0901   1210
  M26                       VPA                0201               2601   1301   5701   0701   1202
  M27                       LTG                0201               2402   4801   5502   0901   1405
  M28                       LTG                0207               2402   4006   4601   0901   0901
  M29                       LTG                0207               1101   4601   5502   0803   1202
  M30                       LTG                0207               3101   4601   5101   1202   1454

*In the HLA naming protocol,"^\*^" separates the HLA locus (A, B and DRB1) from the serotype (32, 33 and 35), eg. HLA-A^\*^ 3201*.

Association Between HLA-A, HLA-B, and HLA-DRB1 Genotypes and AEDs-cADRs, LTG-cADRs, and AAEDs-cADRs
---------------------------------------------------------------------------------------------------

As shown in [Table 5](#T5){ref-type="table"}, OR values of 15 HLA genotypes were \>1. No significant differences in HLA genotype frequencies were observed between the AEDs-cADRs and AEDs tolerant group (*P* \> 0.05).

###### 

Association between HLA-A, HLA-B, HLA-DRB1, and AEDs-cADRs.

  **HLA type**   **Frequency**   **OR(95%CI)**   ***P-*value**         
  -------------- --------------- --------------- --------------------- ------
  A\*0203        1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  A\*0207        5/30 (16.7%)    4/60 (6.7%)     2.800 (0.69\~11.32)   0.15
  A\*2402        4/30 (13.3%)    7/60 (11.7%)    1.165 (0.31\~4.34)    1.00
  A\*3101        3/30 (10.0%)    3/60 (5.0%)     2.111 (0.40\~11.15)   1.00
  A\*3303        3/30 (10.0%)    5/60 (8.3%)     1.222 (0.27\~5.50)    1.00
  B\*1501        2/30 (6.7%)     2/60 (3.3%)     2.071 (0.28\~15.48)   0.60
  B\*1502        0/30 (0.0%)     1/60 (1.7%)     1.017 (0.98\~1.05)    1.00
  B\*4002        1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  B\*4801        1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  B\*5102        1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  DRB1\*0405     2/30 (6.7%)     2/60 (3.3%)     2.071 (0.28\~15.48)   0.60
  DRB1\*0803     3/30 (10.0%)    3/60 (5.0%)     2.111 (0.40\~11.15)   0.40
  DRB1\*1201     1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  DRB1\*1210     1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00
  DRB1\*1302     1/30 (3.3%)     1/60 (1.7%)     2.034 (0.12\~33.70)   1.00

HLA genotyping in 9 patients with LTG-cADRs identified a total of 11 HLA-A types, 13 HLA-B types, and 13 HLA-DRB1 types. In 18 patients of LTG tolerant group, 12 HLA-A types, 17 HLA-B types, and 17 HLA-DRB1 types were identified. OR values of 5 HLA genotypes were \>1. No significant differences in HLA genotype frequency were found between the LTG-cADRs and LTGtolerant group (*P* \> 0.05) ([Table 6](#T6){ref-type="table"}).

###### 

Association between HLA-A, HLA-B, HLA-DRB1, and LTG-cADRs.

  **HLA type**   **Frequency**   **OR(95%CI)**   ***P-*value**       
  -------------- --------------- --------------- ------------------- ------
  A\*0206        4/18 (22.2%)    4/36 (11.1%)    2.28 (0.50\~10.5)   0.29
  A\*2402        2/18 (11.1%)    2/36 (5.6%)     2.12 (0.27\~16.5)   0.48
  A\*3101        2/18 (11.1%)    2/36 (5.6%)     2.12 (0.27\~16.5)   0.48
  B\*5101        4/18 (22.2%)    2/36 (5.6%)     4.85 (0.80\~29.6)   0.76
  DRB1\*3303     3/18 (16.7%)    2/36 (5.6%)     3.40 (0.51\~22.5)   0.19

HLA genotyping in 12 patients with AAEDs-cADRs identified a total of 12 HLA-A types, 15 HLA-B types, and 15 HLA-DRB1 types. In 24 patients of AAEDs tolerant group, 13 HLA-A types, 23 HLA-B types, and 20 HLA-DRB1 types were identified. The OR values of 13 HLA genotypes were \>1. No significant difference in HLA genotype frequency was observed between AAEDs-cADRs and AAEDs tolerant group (*P* \> 0.05) ([Table 7](#T7){ref-type="table"}).

###### 

Association between HLA-A, HLA-B, HLA-DRB1, and AAEDs-cADRs.

  **HLA type**   **Frequency**   **OR(95%CI)**   ***P-*value**         
  -------------- --------------- --------------- --------------------- ------
  A\*0203        1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00
  A\*0207        4/24 (16.7%)    4/48 (8.3%)     2.00 (0.50\~9.70)     0.42
  B\*1302        2/24 (8.3%)     2/48 (4.2%)     2.091 (0.28\~15.83)   0.60
  B\*1501        2/24 (8.3%)     2/48 (4.2%)     2.091 (0.28\~15.83)   0.60
  B\*4002        1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00
  B\*4801        1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00
  B\*5101        6/24 (25.0%)    5/48 (10.4%)    2.87 (0.77\~10.60)    0.16
  DRB1\*0101     1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00
  DRB1\*0405     2/24 (8.3%)     1/48 (2.1%)     4.273 (0.37\~49.68)   0.25
  DRB1\*0701     3/24 (12.5%)    3/48 (6.3%)     2.143 (0.40\~11.15)   0.39
  DRB1\*0803     3/24 (12.5%)    3/48 (6.3%)     2.143 (0.40\~11.15)   0.39
  DRB1\*1201     1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00
  DRB1\*1302     1/24 (4.2%)     1/48 (2.1%)     2.043 (0.12\~34.16)   1.00

Discussion {#s4}
==========

The occurrence of AEDs-cADRs in patients with epilepsy may be influenced by gender, age, initial AEDs dosage, incremental AEDs dosage, and adding rate, with or without a history of allergies, monotherapy or polytherapy, functional status of the liver and kidney, and genetic factors ([@B11]). Chung and colleagues reported that HLA-B^\*^1502 was strongly correlated with CBZ-SJS/TEN in Taiwan Han populations ([@B4]). This result was later supported by others ([@B3]), especially for serious cADRs, with HLA susceptibility genes being the most important factor.

Different AEDs induce different cADR symptoms. In a large-scale study on 3,793 patients with epilepsy taking AEDs, the overall incidence rate of AEDs-cADRs reached 3.61%. The incidence rates of AEDs induced by cADRs were as follows: LTG (11.11%), OXC (8.92%), CBZ (3.80%), PHT (1.98%), PB (0.42%), VPA (0.57%), and LEV (1.65%) ([@B1]). About 88.41% of cADRs were induced by AAEDs of CBZ (47.56%), LTG (17.07%), OXC (9.15%), PHT(9.15%), and PB(5.49%) ([@B12]). These results suggested that AAEDs were more likely to induce cADRs in clinical practice compared with other types of AEDs. In the present study, 80% of patients with AEDs-cADRs were AAEDs-cADRs (12/15). Of these, LTG-cADRs was the most common (9/15).

Correlation studies on HLA genotypes and AEDs-cADRs have been conducted in mainland China ([@B6]--[@B8]), Taiwan ([@B4]), Hong Kong ([@B13]), Southeast Asia ([@B14]--[@B16]), Japan ([@B17]), Korea ([@B18]), Europe ([@B19]), North America ([@B20]), and other regions. The reported correlations between HLA genotypes and AEDs-cADRs have the following characteristics: ① Susceptible genes associated with AEDs-cADRs may be different among different races. For example, HLA-B^\*^1502 is the susceptible gene for AEDs-SJS/TEN in Han Chinese and Southeast Asians. However, in Japan, Europe, and other parts of the world, the susceptible gene for CBZ-cADRs is HLA-A^\*^3101. ② In the Han population in Southeast Asia, HLA-B^\*^1502 may have a susceptibility to aromatic AEDs-SJS/TEN. ③ The incidence rate of AEDs-cADRs is relevant to the distribution rate of HLA-B^\*^1502 alleles among different races. The higher the distribution rate of HLA-B^\*^1502 in the race, the higher the incidence rates for AEDs-cADRs.

Ningxia, located in Northwest China, is an agglomeration of Hui ethnicities that are unlike the southern Han Chinese population genetically. Whether any HLA susceptibility genes are responsible for the occurrence of AEDs-cADRs among the northwestern population in China is not known. Therefore, the distribution rate of HLA genotypes was compared in the following groups: all patients in the AEDs-cADRs group vs. patients in the AEDs tolerant group, AAEDs-cADRs group vs. AAEDs tolerant group, and LTG-cADRs group vs. LTGtolerant group. The results suggested that the HLA-A, HLA-B, and HLA-DRB1 genotype distribution frequencies were not statistically significantly different between the two groups.

The present study had some limitations that might have impacted the outcome. First, selecting a large number of patients with AEDs-cADRs was difficult. Nine patients with LTG-cADRs were enrolled in this study. However, only one patient with CBZ-cADRs, one patient with PHT-cADRs, two patients with CBZ-cADRs, two patients with LEV-cADRs, and one patient with VPA-cADRs. Future studies focusing on large-sample populations with similar epilepsy and AEDs should be conducted. Second, the study did not adjust for age, gender, and other possible confounding variables during statistical analysis due to the small sample size. This might have had a minor impact on the results because the patients and controls were matched using a nested case--control design.

Conclusions {#s5}
===========

The presentstudy did not find a significant association between any HLA genotypes and AEDs-cADRs in patients with epilepsy in Northwest China. Future studies using larger cohorts are needed to verify this observation.
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